CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
FDA approves Tecartus, cell-based gene therapy to treat relapsed or refractory MCL in adults Read more